Subchondroplasty® (SCP) Provides Resolution of Symptoms and Functional Improvements in Mild-to-Moderate Knee Osteoarthritis with Persistent Bone Marrow Lesions: 12-Month Follow-Up Results from a Multicentric Open-Label Prospective Clinical Trial

Other authors

Institut Català de la Salut

[Di Matteo B, Anzillotti G, Conte P] IRCCS Humanitas Research Hospital, Rozzano, Italy. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. [Angele P] Department of Trauma and Reconstructive Surgery, University Hospital Regensburg, Regensburg, Germany. Sporthopaedicum Regensburg/Straubing, Regensburg, Germany. [Emans P] Joint Preserving Clinic, Department of Orthopedic Surgery, Maastricht University Medical Center, Maastricht, The Netherlands. [Minguell-Monyart J] Servei de Cirurgia Ortopèdica i Traumatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2025-05-29T06:18:17Z

2025-05-29T06:18:17Z

2025-06



Abstract

Bone marrow lesions; Osteoarthritis; Subchondroplasty


Lesions de medul·la òssia; Osteoartritis; Subcondroplàstia


Lesiones de médula ósea; Osteoartritis; Subcondroplastia


Introduction. Bone marrow lesions (BMLs) are MRI-visible subchondral bone alterations, highly correlated with symptoms in the knee. Subchondroplasty (SCP) is able to fill the subchondral defects associated with BMLs using an injectable bone substitute material. The aim of the present study is to evaluate the 12-month outcomes of the SCP in the treatment of symptoms of mild-to-moderate knee osteoarthritis (OA) patients with persistent BMLs of the knee. Materials and Methods. Subjects affected by BMLs of the femoral condyle or tibial plateau that were present for >3 months and not responsive to conservative treatments were enrolled in this prospective multicenter trial. All the patients underwent SCP. Follow-up was conducted at 1, 3, 6 and 12 months. All subjects completed Numerical Rating Scale (NRS) for pain, Knee Injury and Osteoarthritis Outcome (KOOS) score, Euro Quality of life-5 dimensions (EQ-5D) score, and a subject global satisfaction scale. Demographic information of the patients was also collected. Results. A total of 79 patients completed the 12-month follow-up. Statistically significant improvements on all clinical scales were registered from baseline to the 12-month follow-up. No severe adverse events were reported. Four patients were considered failed. A 12-month subgroup analysis was performed to evaluate the possible correlation between all the KOOS subscales and age, gender, number of BMLs, location of BMLs, and Kellgren-Lawrence grade: no statistically significant associations were observed. Conclusion. SCP is a safe and effective procedure for the treatment of symptoms related to persisting BMLs in mild-to-moderate osteoarthritic knees, with a low failure rate up to 12 months’ evaluation.


The presented study was fully sponsored by Zimmer Biomet.

Document Type

Article


Published version

Language

English

Publisher

SAGE Publications

Related items

CARTILAGE;16(2)

https://doi.org/10.1177/19476035241264011

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial 4.0 International

http://creativecommons.org/licenses/by-nc/4.0/

This item appears in the following Collection(s)